Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients

AIDS. 2004 Jan 2;18(1):123-7. doi: 10.1097/00002030-200401020-00016.

Abstract

Genotypes in nine highly protease inhibitor (PI)-experienced patients were studied before and after lopinavir/ritonavir (LPV/r) treatment. Resistance to amprenavir was the rule both before and after LPV/r treatment. Treatment with LPV/r can select for the 50 V mutation. In this setting, significant differences in the inference of the amprenavir phenotype from genotype were observed when using different algorithms.

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Carbamates
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Female
  • Furans
  • Genotype
  • HIV / genetics
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Lopinavir
  • Male
  • Middle Aged
  • Mutation / genetics
  • Pyrimidinones / therapeutic use*
  • RNA, Viral / blood
  • Retrospective Studies
  • Ritonavir / therapeutic use*
  • Sulfonamides / therapeutic use*

Substances

  • Anti-Retroviral Agents
  • Carbamates
  • Furans
  • HIV Protease Inhibitors
  • Pyrimidinones
  • RNA, Viral
  • Sulfonamides
  • Lopinavir
  • amprenavir
  • Ritonavir